Eudaimonic well-being tied to ovarian tumor neuroeffector

Eudaimonic well-being tied to ovarian tumor neuroeffector

(HealthDay)—Eudaimonic well-being is associated with lower tumor norepinephrine (NE) in women with epithelial ovarian cancer, according to a study published in the Oct. 1 issue of Cancer.

Lauren Z. Davis, from the University of Iowa in Iowa City, and colleagues assessed how two different aspects of well-being (eudaimonic and positive affect) and were associated with NE in 365 patients with . High-performance liquid chromatography with electrochemical detection was used to measure tumor NE in frozen tissue samples.

The researchers found that eudaimonic well-being, positive affect, and psychological distress modeled as distinct, but correlated constructs. A good model fit was found for structural equation modeling analysis that included physical well-being, stage of disease, histology, psychological treatment history, beta-blocker use, and caffeine use as covariates. This model demonstrated that eudaimonic well-being was related to lower tumor NE (P = 0.045), while no effects were found for positive affect or psychological distress.

"Because adrenergic signaling is implicated in tumor progression, increasing eudaimonic well-being may improve both psychological and physiologic resilience in patients with ovarian cancer," the authors write.

Two authors disclosed financial ties to the medical device industry.

More information: Abstract
Full Text (subscription or payment may be required)

Journal information: Cancer

Copyright © 2015 HealthDay. All rights reserved.

Citation: Eudaimonic well-being tied to ovarian tumor neuroeffector (2015, September 29) retrieved 23 April 2024 from https://medicalxpress.com/news/2015-09-eudaimonic-well-being-tied-ovarian-tumor.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Generic heart medication shown to prolong ovarian cancer patients' survival

15 shares

Feedback to editors